Non-small Cell Lung Cancer Therapeutics Market cover

Non-small Cell Lung Cancer Therapeutics Market by Drugs (Iressa, Alimta, Tarceva, Avastin, Zykadia, Xalkori, Cyramza, Tagrisso, Opdivo, and Alecensa) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: CG-2351
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 1
  • No. Of Pages: 186
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global non-small cell lung cancer therapeutics market size is expected to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is accredited to the increasing patient population and entry of several drugs for the treatment of lung cancer.

Non-small Cell Lung Cancer Therapeutics Market summary

Non-small cell lung cancer (NSCLC) therapeutics is one of the common types of the treatment for cancer since over 90% of the all lung cancer are of non-small cell lung cancer. NSCLC therapeutics focuses on this type of cancer treatment ranging from initial stage to late stage. Rising incidences of NSCLC across the world due to rising air pollution and smoking habits among a large number of the global population is expected to positively affect the market in the coming years. As per the estimation by the American Cancer Society, about 223,390 new lung cancer patients were reported in 2016 in the US alone.

The presence of a powerful pipeline for NSCLC treatment and introduction of new drugs for the targeted treatment present key aspects for the market growth in the coming years. For instance, a drug “fruquintinib (HMPL-013)” which was formulated to diagnose advanced NSCLC is in its clinical trial phase. Moreover, the Merck KGaA developed “Avelumab,” which is presently one of the key drugs in the pipeline. It is a human monoclonal PD-L1 antigen. The development of these advanced diagnosis are one of the key factors for the market expansion.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing investment by key market players in R&D activities to enhance and improve NSCLC therapy model is expected to accelerate the market growth.
  • Rising incidences of lung cancer across the globe due to high-level of air pollution and changing lifestyle such as increasing number of smokers among the global population is expected to drive the market expansion in the coming years.
  • Rapid development of advanced treatments for NSCLC and favorable government policies for the expansion of cancer treatment facilities are expected to boost the market growth during the forecast period.
  • High cost of the cancer treatment and lack of accessibility to advanced healthcare facilities for the cancer treatment in remote parts of developing countries are key challenges that can hamper the market expansion.

Scope of the Report                         

The report on the global non-small cell lung cancer therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Non-small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs (Iressa, Alimta, Tarceva, Avastin, Zykadia, Xalkori, Cyramza, Tagrisso, Opdivo, and Alecensa)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

GlaxoSmithKline plc; Novartis International AG; AstraZeneca plc; Eli Lilly and Company; Pfizer Inc.; and F. Hoffmann-La Roche AG.

Market Segment Insights

Alecensa segment is expected to grow at a rapid pace

Based on drugs, the global non-small cell lung cancer therapeutics market is divided into iressa, alimta, tarceva, avastin, zykadia, xalkori, cyramza, tagrisso, opdivo, and alecensa. The alecensa segment is expected to grow at a rapid pace during the projected period owing to increasing geographical penetration of the drug, rising awareness of advanced drugs for cancer treatment, and progression-free survival rate. However, the tagrisso segment is anticipated to expand considerably during the forecast period due to latest approvals in several geographical regions and rising demand of the drug.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a large share of the market in 2019 and is anticipated to constitute a key market share during the projected period due to presence of a strong pipeline and research activities by various industry players in the region. The market of Asia Pacific, however, is anticipated to expand at a robust CAGR during the forecast period owing to presence of less stringent regulatory procedures for approval and a large patient pool in the region.

Non-small Cell Lung Cancer Therapeutics Market region

Segments

Segments Covered in the Report

The global non-small cell lung cancer therapeutics market has been segmented on the basis of

Drugs

  • Iressa
  • Alimta
  • Tarceva
  • Avastin
  • Zykadia
  • Xalkori
  • Cyramza
  • Tagrisso
  • Opdivo
  • Alecensa

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • GlaxoSmithKline plc.
  • Novartis International AG
  • AstraZeneca plc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG

Competitive Landscape

Key players competing in the global non-small cell lung cancer therapeutics market are GlaxoSmithKline plc; Novartis International AG; AstraZeneca plc; Eli Lilly and Company; Pfizer Inc.; and F. Hoffmann-La Roche AG. The main market players are continuously engaged in the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to expand their business operations in the market. For instance, Tagrisso was given approval in Japan for the diagnosis of EGFR T790M mutation-positive recurrent or inoperable NSCLC in March 2016.

Non-small Cell Lung Cancer Therapeutics Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Non-small Cell Lung Cancer Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Non-small Cell Lung Cancer Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Non-small Cell Lung Cancer Therapeutics Market - Supply Chain
  4.5. Global Non-small Cell Lung Cancer Therapeutics Market Forecast
     4.5.1. Non-small Cell Lung Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Non-small Cell Lung Cancer Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Non-small Cell Lung Cancer Therapeutics Market Absolute $ Opportunity
5. Global Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
6. North America Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
8. Europe Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Non-small Cell Lung Cancer Therapeutics Market: Market Share Analysis
  11.2. Non-small Cell Lung Cancer Therapeutics Distributors and Customers
  11.3. Non-small Cell Lung Cancer Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. GlaxoSmithKline plc.
     11.4.2. Novartis International AG
     11.4.3. AstraZeneca plc.
     11.4.4. Eli Lilly and Company
     11.4.5. Pfizer Inc.
     11.4.6. F. Hoffmann-La Roche AG

Segments Covered in the Report

The global non-small cell lung cancer therapeutics market has been segmented on the basis of

Drugs

  • Iressa
  • Alimta
  • Tarceva
  • Avastin
  • Zykadia
  • Xalkori
  • Cyramza
  • Tagrisso
  • Opdivo
  • Alecensa

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • GlaxoSmithKline plc.
  • Novartis International AG
  • AstraZeneca plc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG

Key players competing in the global non-small cell lung cancer therapeutics market are GlaxoSmithKline plc; Novartis International AG; AstraZeneca plc; Eli Lilly and Company; Pfizer Inc.; and F. Hoffmann-La Roche AG. The main market players are continuously engaged in the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to expand their business operations in the market. For instance, Tagrisso was given approval in Japan for the diagnosis of EGFR T790M mutation-positive recurrent or inoperable NSCLC in March 2016.

Non-small Cell Lung Cancer Therapeutics Market keyplayers

Buy Report